I am very sure I have been consistently arguing that any chance of approval depended on CMA with a confirmatory Phase 3 trial, while also explaining why a Phase 4 trial would not be sufficient.
Were you surprised to learn that Missling had changed the MAA to seek CMA instead of full approval without informing investors?
The outcome is that the Phase 3 trial Missling rightly suggested would be initiated, but didn’t, would, as I and others have said many times, have been the right thing to do. Instead, Anavex now has nothing approvable as a fallback and faces roughly three more years of zero revenue ahead of the company and new greater fools.
If you could stretch to be honest with yourself, you would admit that I have been completely consistent, as I have repeated this so often that it has clearly frustrated you over the years.
For the record, I don’t care for or need any admissions or apologies from you, and I am quite content with having sold $AVXL on nearly every irrational spike, except for one or two recent FOMO-induced misses. I blame no one but myself for that, though not by much.
More than anything, I just hope some have learned something along the way and still have some dry powder left to try again and do better.
Market Data 
Markets 
AI
